Literature DB >> 9322511

T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope.

A Hombach1, C Heuser, R Sircar, T Tillmann, V Diehl, W Kruis, C Pohl, H Abken.   

Abstract

BACKGROUND & AIMS: Chimeric receptors with specificity for defined tumor antigens are valuable tools for targeting cytolytic T cells specifically to tumor cells. The aim of this study, for the situation of gastrointestinal cancer, was to investigate the generation of a chimeric T cell receptor that specifically binds the tumor antigen TAG72 (CA72-4) and transmits a signal for cellular activation.
METHODS: A single-chain antibody (scFv) was derived from the monoclonal anti-TAG72 antibody B72.3 by phage display techniques (B72.3-scFv) and fused to the signaling unit of the Fc epsilon-RI receptor gamma chain, resulting in a chimeric signaling receptor, B72.3-scFv-gamma.
RESULTS: The B72.3-scFv and the chimeric B72.3-scFv-gamma receptor bound specifically to the TAG72 antigen. After transfection, T cells expressing the chimeric B72.3-scFv-gamma specifically recognized TAG72 positive cells. Cross-linking of the chimeric receptor with antigen resulted in interleukin 2 release and cytolytic activity against TAG72 positive tumor cells in vitro.
CONCLUSIONS: T cells equipped with the chimeric anti-TAG72 receptor can be specifically activated to target and lyse TAG72 positive gastrointestinal tumor cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9322511     DOI: 10.1053/gast.1997.v113.pm9322511

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

Review 1.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

2.  A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.

Authors:  A Hombach; C Schlimper; E Sievers; S Frank; H H Schild; T Sauerbruch; I G H Schmidt-Wolf; H Abken
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

3.  A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.

Authors:  Ming-Hsien Chien; Wei-Min Chang; Wei-Jiunn Lee; Yu-Chan Chang; Tsung-Ching Lai; Derek V Chan; Rahul Sharma; Yuan-Feng Lin; Michael Hsiao
Journal:  Mol Cancer Ther       Date:  2017-03-14       Impact factor: 6.261

4.  Development of oligoclonal nanobodies for targeting the tumor-associated glycoprotein 72 antigen.

Authors:  Zahra Sharifzadeh; Fatemeh Rahbarizadeh; Mohammad Ali Shokrgozar; Davoud Ahmadvand; Fereidoun Mahboudi; Fatemeh Rahimi Jamnani; Seyed Hamid Aghaee Bakhtiari
Journal:  Mol Biotechnol       Date:  2013-06       Impact factor: 2.695

Review 5.  Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy.

Authors:  Carlos A Ramos; Gianpietro Dotti
Journal:  Expert Opin Biol Ther       Date:  2011-04-04       Impact factor: 4.388

Review 6.  Design and development of therapies using chimeric antigen receptor-expressing T cells.

Authors:  Gianpietro Dotti; Stephen Gottschalk; Barbara Savoldo; Malcolm K Brenner
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Strategies to genetically engineer T cells for cancer immunotherapy.

Authors:  Timothy T Spear; Kaoru Nagato; Michael I Nishimura
Journal:  Cancer Immunol Immunother       Date:  2016-05-02       Impact factor: 6.968

Review 8.  Engineered T cells for cancer treatment.

Authors:  Usanarat Anurathapan; Ann M Leen; Malcolm K Brenner; Juan F Vera
Journal:  Cytotherapy       Date:  2013-11-13       Impact factor: 5.414

Review 9.  CAR T-cell immunotherapy: The path from the by-road to the freeway?

Authors:  Lynsey M Whilding; John Maher
Journal:  Mol Oncol       Date:  2015-10-23       Impact factor: 6.603

Review 10.  CAR T-cell therapy in mature lymphoid malignancies: clinical opportunities and challenges.

Authors:  Mayur Narkhede; Amitkumar Mehta; Stephen M Ansell; Gaurav Goyal
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.